Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4904-4910

  Egelund, Eric F ^a   Weiner, Marc ^b   Singh, Rajendra P ^c   Prihoda, Thomas J ^d   Gelfond, Jonathon A L ^d   Derendorf, Hartmut ^a   MacKenzie, William R ^e   Peloquin, Charles A ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25-DESACETYLRIFAPENTINE; PLASMA PROTEIN; PROTEIN BINDING; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLACK PERSON; BLOOD; CAUCASIAN; DRUG EFFECTS; ETHNOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; TUBERCULOSIS, PULMONARY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBIOTICS, ANTITUBERCULAR; BIOTRANSFORMATION; BLOOD PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84905397050     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01730-13     Document Type: Article

References (16)

1. Wright JD, Boudinot FD, Ujhelyi MR. 1996. Measurement and analysis of unbound drug concentrations. Clin. Pharmacokinet. 30:445-462. http://dx.doi.org/10.2165/00003088-199630060-00003.
2. Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. 1998. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 26:732-738
3. NIH. PRIFTIN (rifapentine) tablet, film coated [sanofi-aventis U. S. LLC]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=F768E337-A948-420A- 9FBE-9BE359C7A170ection-8.1. Accessed 14 June 2013.
4. Rastogi N, Goh KS, Berchel M, Bryskier A. 2000. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J. Antimicrob. Chemother. 46:565-570. http://dx.doi.org/10.1093/jac/46.4.565.
5. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, MacKenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. 2010. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54:4192-4200. http://dx.doi.org/10.1128/AAC.00353- 10.
6. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206:1030-1040. http://dx.doi.org/10.1093/infdis/jis461.
7. Savic RM, Weiner M, Mac Kenzie WW, Helig C, Dooley K, Engle M, Nsubuga P, Phan H, Peloquin C, Dorman S, for the Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. 2013. PKPD analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium Studies 29 and 29×. Abstr. 6th Int. Workshop Clin. Pharmacol. Tuberc. Drugs, abstr 11, p11. http://regist2.virology-education.com/ abstractbook/programbook-6thTB-PK.pdf.
8. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S, Tuberculosis Trials Consortium. 2004. Pharmacokinetics of rifapentine at 600, 900, and 1, 200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197. http://dx.doi.org/10.1164/rccm.200311-1612OC.
9. Heifets LB, Lindholm-Levy PJ, Flory MA. 1990. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141:626-630. http://dx.doi.org/10.1164/ ajrccm/141.3.626.
10. Ramakrishnan K, Shenbagarathai R, Kavitha K, Uma A, Balasubramaniam R, Thirumalaikolundusubramanian P. 2008. Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn. J. Infect. Dis. 61:202-204.
11. Mehta SH, Astemborski J, Sterling TR, Thomas DL, Vlahov D. 2006. Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res. Hum. Retroviruse. 22:14-21. http://dx.doi.org/10.1089/aid.2006.22.14.
12. Matos ED, Moreira Lemos AC. 2006. Association between serum albumin levels and in-hospital deaths due to tuberculosis. Int. J. Tuberc. Lung Dis. 10:1360-1366.
13. Boman G, Ringberger VA. 1974. Binding of rifampicin by human plasma proteins. Eur. J. Clin. Pharmacol. 7:369-373.
14. Johnson JA, Livingston TN. 1997. Differences between blacks and whites in plasma protein binding of drugs. Eur. J. Clin. Pharmacol. 51:485-488. http://dx.doi.org/10.1007/s002280050235.
15. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P. 2005. The extraordinary ligand binding properties of human serum albumin. IUBMB Lif. 57:787-796. http://dx.doi.org/10.1080/15216540500404093.
16. Woo J, Cheung W, Chan R, Chan HS, Cheng A, Chan K. 1996. In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin. Biochem. 29:175-177. http://dx.doi.org/10.1016/0009-9120(95)02024-1.